

Jesper BÃ¸je Andersen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8023989/publications.pdf>

Version: 2024-02-01

106
papers

8,952
citations

61687

45
h-index

49824

91
g-index

108
all docs

108
docs citations

108
times ranked

12748
citing authors

#	ARTICLE	IF	CITATIONS
1	The protease inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. <i>Liver International</i> , 2022, 42, 233-248.	1.9	15
2	Mucosal-associated invariant T cell tumor infiltration predicts long-term survival in cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 1154-1168.	3.6	14
3	Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. <i>Theranostics</i> , 2022, 12, 260-276.	4.6	16
4	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. <i>Hepatology</i> , 2022, 76, 1617-1633.	3.6	15
5	miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. <i>Hepatology Communications</i> , 2022, 6, 1467-1481.	2.0	8
6	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
7	Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. <i>Advances in Cancer Research</i> , 2022, , .	1.9	1
8	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>Journal of Hepatology</i> , 2022, 77, 177-190.	1.8	11
9	Lipid alterations in chronic liver disease and liver cancer. <i>JHEP Reports</i> , 2022, 4, 100479.	2.6	69
10	Mutational signatures and processes in hepatobiliary cancers. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 367-382.	8.2	2
11	Stromal yin-yang of myfibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2022, , .	3.6	0
12	Involvement of Epigenomic Factors in Bile Duct Cancer. <i>Seminars in Liver Disease</i> , 2022, 42, 202-211.	1.8	0
13	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. <i>Journal of Hepatology</i> , 2022, 77, 1047-1058.	1.8	7
14	Molecular Targets in Cholangiocarcinoma. <i>Hepatology</i> , 2021, 73, 62-74.	3.6	26
15	Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. <i>Journal of Hepatology</i> , 2021, 74, 1132-1144.	1.8	30
16	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021, 70, 1345-1361.	6.1	59
17	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. <i>Cancer Research</i> , 2021, 81, 2874-2887.	0.4	27
18	Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 1373-1385.	1.8	60

#	ARTICLE	IF	CITATIONS
19	Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. <i>Hepatology</i> , 2021, 74, 2007-2020.	3.6	12
20	Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. <i>JCI Insight</i> , 2021, 6, .	2.3	9
21	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. <i>BMC Cancer</i> , 2021, 21, 1079.	1.1	14
22	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021, 73, 103661.	2.7	31
23	Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance. <i>Haematologica</i> , 2021, 106, 1762-1766.	1.7	6
24	Identification of a Pan- γ -Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma. <i>Hepatology</i> , 2020, 71, 196-213.	3.6	29
25	Dual-initiation promoters with intertwined canonical and TCT/TOP transcription start sites diversify transcript processing. <i>Nature Communications</i> , 2020, 11, 168.	5.8	37
26	Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing. <i>Rna</i> , 2020, 26, 1726-1730.	1.6	5
27	Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. <i>Journal of Hepatology</i> , 2020, 73, 1007-1009.	1.8	9
28	Ancestrally Duplicated Conserved Noncoding Element Suggests Dual Regulatory Roles of HOTAIR in cis and trans. <i>IScience</i> , 2020, 23, 101008.	1.9	9
29	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 5655-5667.	3.2	21
30	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020, 9, 721.	1.8	63
31	Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 2241-2251.	1.2	1
32	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
33	Epigenome Remodeling in Cholangiocarcinoma. <i>Trends in Cancer</i> , 2019, 5, 335-350.	3.8	36
34	The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. <i>Oncogenesis</i> , 2019, 8, 61.	2.1	27
35	Therapeutic Potential of Pharmacoeugenetics in Cholangiocarcinoma. , 2019, , 551-562.		0
36	Cholangiocarcinoma: State-of-the-art knowledge and challenges. <i>Liver International</i> , 2019, 39, 5-6.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. <i>Liver International</i> , 2019, 39, 32-42.	1.9	21
38	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. <i>Hepatology</i> , 2019, 70, 1246-1261.	3.6	41
39	A morphogenetic EphB/EphrinB code controls hepatopancreatic duct formation. <i>Nature Communications</i> , 2019, 10, 5220.	5.8	14
40	Metabolic rearrangements in primary liver cancers: cause and consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 748-766.	8.2	144
41	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. <i>British Journal of Pharmacology</i> , 2019, 176, 787-800.	2.7	39
42	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. <i>International Journal of Cancer</i> , 2019, 144, 2782-2794.	2.3	19
43	Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. <i>Trends in Cancer</i> , 2018, 4, 239-255.	3.8	92
44	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2018, 68, 949-963.	3.6	106
45	Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. <i>Liver International</i> , 2018, 38, 113-124.	1.9	33
46	Epigenome dysregulation in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1423-1434.	1.8	31
47	Reply. <i>Gastroenterology</i> , 2018, 154, 260-261.	0.6	0
48	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. <i>Gastroenterology</i> , 2018, 154, 1066-1079.e5.	0.6	94
49	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	2.9	134
50	Single cell profiling reveals window for immunotherapy in liver cancers. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 48-51.	0.7	3
51	RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation. <i>PLoS ONE</i> , 2018, 13, e0196979.	1.1	1
52	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. <i>Nature Communications</i> , 2017, 8, 14294.	5.8	119
53	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 72-83.	1.8	81
54	Advances in the molecular characterization of liver tumors. , 2017, , 133-138.e2.		0

#	ARTICLE	IF	CITATIONS
55	Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Review of Gastroenterology and Hepatology, 2017, 11, 349-356.	1.4	16
56	Association of Aflatoxin and Gallbladder Cancer. Gastroenterology, 2017, 153, 488-494.e1.	0.6	49
57	High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular Carcinogenesis, 2017, 56, 2146-2157.	1.3	17
58	Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 2017, 32, 57-70.e3.	7.7	324
59	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
60	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Scientific Reports, 2017, 7, 17667.	1.6	60
61	Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell-Based Model. Gastroenterology, 2017, 152, 19-21.	0.6	4
62	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	1.8	130
63	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget, 2017, 8, 48688-48700.	0.8	15
64	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	0.6	17
65	Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology, 2016, 63, 1888-1899.	3.6	40
66	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964
67	Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs. Nucleic Acids Research, 2016, 44, 3070-3081.	6.5	38
68	Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. Digestive Diseases, 2016, 34, 440-451.	0.8	20
69	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
70	Heterogeneity Among Liver Cancer—A Hurdle to Optimizing Therapy. Gastroenterology, 2016, 150, 818-821.	0.6	7
71	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. Journal of Hepatology, 2015, 62, 198-207.	1.8	66
72	Fibrolamellar Hepatocellular Carcinoma: A Rare but Distinct Type of Liver Cancer. Gastroenterology, 2015, 148, 707-710.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. <i>Hepatic Oncology</i> , 2015, 2, 79-93.	4.2	16
74	Curcumin effectively inhibits oncogenic NF- κ B signaling and restrains stemness features in liver cancer. <i>Journal of Hepatology</i> , 2015, 63, 661-669.	1.8	237
75	Functional and genetic deconstruction of the cellular origin in liver cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 653-667.	12.8	249
76	Molecular pathogenesis of intrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 101-113.	1.4	51
77	A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. <i>Hepatic Oncology</i> , 2014, 1, 143-157.	4.2	16
78	Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. <i>Hepatology</i> , 2014, 59, 911-923.	3.6	382
79	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. <i>Journal of Hepatology</i> , 2014, 60, 346-353.	1.8	85
80	Epigenetic reprogramming modulates malignant properties of human liver cancer. <i>Hepatology</i> , 2014, 59, 2251-2262.	3.6	75
81	p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. <i>Cell</i> , 2014, 158, 579-592.	13.5	176
82	MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism. <i>Cancer Research</i> , 2014, 74, 5903-5913.	0.4	71
83	Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. <i>Cancer Research</i> , 2014, 74, 4752-4761.	0.4	74
84	Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. <i>Journal of Hepatology</i> , 2014, 60, 855-865.	1.8	262
85	Molecular constituents of the extracellular matrix in rat liver mounting a hepatic progenitor cell response for tissue repair. <i>Fibrogenesis and Tissue Repair</i> , 2013, 6, 21.	3.4	17
86	Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities. <i>Gastroenterology</i> , 2013, 144, 687-690.	0.6	18
87	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. <i>Gastroenterology</i> , 2013, 145, 221-231.	0.6	153
88	Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. <i>Genes and Development</i> , 2013, 27, 1706-1717.	2.7	90
89	Genetic profiling of intrahepatic cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 266-272.	1.0	82
90	Next-Generation Sequencing: Application in Liver Cancer – Past, Present and Future?. <i>Biology</i> , 2012, 1, 383-394.	1.3	16

#	ARTICLE	IF	CITATIONS
91	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. <i>Gastroenterology</i> , 2012, 142, 1021-1031.e15.	0.6	443
92	Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2012, 56, 1792-1803.	3.6	203
93	mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 139ra84.	5.8	88
94	Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. <i>Hepatology</i> , 2011, 54, 1031-1042.	3.6	72
95	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. <i>Journal of Experimental Medicine</i> , 2011, 208, 1963-1976.	4.2	183
96	Coactivation of AKT and β -Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors. <i>Cancer Research</i> , 2011, 71, 2718-2727.	0.4	73
97	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. <i>Journal of Cell Biology</i> , 2011, 194, i11-i11.	2.3	0
98	Progenitor-derived hepatocellular carcinoma model in the rat. <i>Hepatology</i> , 2010, 51, 1401-1409.	3.6	118
99	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. <i>Science Translational Medicine</i> , 2010, 2, 54ra77.	5.8	92
100	Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2010, 70, 8264-8269.	0.4	65
101	Loss of c-Met Disrupts Gene Expression Program Required for G2/M Progression during Liver Regeneration in Mice. <i>PLoS ONE</i> , 2010, 5, e12739.	1.1	66
102	Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. <i>RNA Biology</i> , 2009, 6, 305-315.	1.5	56
103	UBE1L causes lung cancer growth suppression by targeting cyclin D1. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3780-3788.	1.9	72
104	Post-transcriptional Regulation of RNase-L Expression Is Mediated by the 3' UTR of Its mRNA. <i>Journal of Biological Chemistry</i> , 2007, 282, 7950-7960.	1.6	39
105	Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. <i>FEBS Journal</i> , 2004, 271, 628-636.	0.2	25
106	The Altered Serum Lipidome and its Diagnostic Potential for Non-Alcoholic Fatty Liver (NAFL)-Associated Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1